Agilent Technologies Inc. A

Agilent Technologies, Inc. se dedica a proporcionar soluciones enfocadas en aplicaciones que incluyen instrumentos, software, servicios y consumibles para todo el flujo de trabajo de laboratorio. El segmento de ciencias de la vida y mercados aplicados de la empresa ofrece soluciones enfocadas en aplicaciones, que incluyen instrumentos, consumibles y software que permiten a los clientes identificar, cuantificar y analizar las propiedades físicas y biológicas de sustancias y productos. Su segmento de diagnóstico y genómica incluye los negocios de genómica, fabricación de ácidos nucleicos por contrato e investigación y desarrollo, patología, diagnóstico complementario, asociación de reactivos y análisis biomolecular. El segmento Agilent CrossLab de la empresa ofrece una cartera de servicios que consiste en reparaciones, piezas, mantenimiento, instalaciones, capacitación, soporte de cumplimiento, software como servicio, gestión de activos, consultoría y varios otros servicios personalizados para apoyar las operaciones de laboratorio de los clientes.

Con 6 acciones de A (USD 1.025,69) habrías recibido USD 4,68 en dividendos en los últimos 12 meses.

A separó parte de su negocio en una nueva empresa (spin-off) el 3 de noviembre de 2014. Sus accionistas recibieron acciones de la nueva compañía, y por eso el precio histórico de A está ajustado.

• GlobeNewswire Inc. 5 oct

  Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR

  The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

  

• GlobeNewswire Inc. 5 oct

  Global Oligonucleotide Synthesis Reagents Market Size, Share, and Forecast, 2026-2033 | Therapeutics Demand Fuels 11.9% CAGR and USD 1.75 Billion Opportunity

  The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

  

• GlobeNewswire Inc. 5 oct

  Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion

  The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.

  

• Zacks Investment Research 1 oct

  Why Is Medtronic (MDT) Down 6.4% Since Last Earnings Report?

  Medtronic reported strong Q1 fiscal 2027 results with adjusted EPS of $1.45 (up 15.1% YoY) and revenues of $9.76 billion (up 13.7% YoY), both beating consensus estimates. The company raised full-year organic revenue growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. However, shares have declined 6.4% since the earnings report, underperforming the S&P 500. Analyst estimates have trended downward post-earnings, and the stock carries a Zacks Rank #3 (Hold) rating.

  

• Zacks Investment Research 23 sept

  If You Invested $1000 in Agilent Technologies a Decade Ago, This is How Much It'd Be Worth Now

  A $1,000 investment in Agilent Technologies made in September 2016 would be worth $3,583.89 as of September 23, 2026, representing a 258.39% gain. This outperforms the S&P 500's 256.64% return over the same period. Analysts expect continued upside driven by instrument replacement demand, pharma exposure, and expanding specialty CDMO activity, though headwinds remain in academia, government, Europe, and China.